Levetiracetam (All indications) updated on 04-22-2025

Elective/induced termination of pregnancy

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S16096
R66786		 Hoeltzenbein (Levetiracetam), 2024 Elective termination of pregnancy at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: Yes 1.05 [0.26;4.23] 7/221   6/469 13 221
ref
S12676
R47900		 Mari (Levetiracetam), 2022 Abortion throughout pregnancy retrospective cohort exposed to other treatment, sick Adjustment: No 0.64 [0.01;34.59] C 0/17   0/11 0 17
ref
S12886
R48696		 Hosny (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2021 Induced abortion 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 0.01 [0.00;0.92] C
excluded (control group) 		0/67   0/1 0 67
ref
S12887
R48699		 Hosny (Levetiracetam) (Controls unexposed, sick), 2021 Induced abortion 1st trimester prospective cohort unexposed, sick Adjustment: No 0.31 [0.01;16.03] C 0/67   0/21 0 67
ref
Total 3 studies 0.88 [0.25;3.08] 13 305
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Hoeltzenbein (Levetiracetam), 2024Hoeltzenbein, 2024 1 1.05[0.26; 4.23]1322180%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: criticalROB reporting: critical Mari (Levetiracetam), 2022Mari, 2022 2 0.64[0.01; 34.59]01710%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: unclear Hosny (Levetiracetam) (Controls unexposed, sick), 2021Hosny, 2021 3 0.31[0.01; 16.03]06710%ROB confusion: criticalROB selection: moderateROB classification: unclearROB missing: lowROB mesure: unclearROB reporting: moderate Total (3 studies) I2 = 0% 0.88[0.25; 3.08]133050.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Levetiracetam; 2: Levetiracetam; 3: Levetiracetam) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.88[0.25; 3.08]133050%NAHoeltzenbein (Levetiracetam), 2024 Mari (Levetiracetam), 2022 Hosny (Levetiracetam) (Controls unexposed, sick), 2021 3 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.31[0.01; 16.03]-67 -NAHosny (Levetiracetam) (Controls unexposed, sick), 2021 1 exposed to other treatment, sickexposed to other treatment, sick 0.99[0.27; 3.71]132380%NAHoeltzenbein (Levetiracetam), 2024 Mari (Levetiracetam), 2022 2 Tags Adjustment   - No  - No 0.44[0.03; 7.32]-840%NAMari (Levetiracetam), 2022 Hosny (Levetiracetam) (Controls unexposed, sick), 2021 2   - Yes  - Yes 1.05[0.26; 4.24]13221 -NAHoeltzenbein (Levetiracetam), 2024 1 All studiesAll studies 0.88[0.25; 3.08]133050%NAHoeltzenbein (Levetiracetam), 2024 Mari (Levetiracetam), 2022 Hosny (Levetiracetam) (Controls unexposed, sick), 2021 30.15.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 12886

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls Out of scale0.31[0.01; 16.03]-67 -NAHosny (Levetiracetam) (Controls unexposed, sick), 2021 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale0.35[0.03; 4.39]1330547%NAHoeltzenbein (Levetiracetam), 2024 Mari (Levetiracetam), 2022 Hosny (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2021 30.510.01.0